pharmaceutical products, the subject of this publication is the conclusion of non-exclusive discount agreements in accordance with section 130a (8) sgb v for drugs containing the active ingredient gefitinib (atc code according to who: l01xe02) as part of a so-called "open-house model". all interested and suitable pharmaceutical companies are offered the conclusion of a discount agreement in accordance with section 130a (8) sgb v, subject to uniform conditions and a uniform access procedure. there is no exclusivity. the purchase quantity is unknown when the agreement is concluded and depends in particular on the demand from the insured, the development of the number of insured, the preion behavior of the contract doctors and the dispensing and stocking behavior of the public pharmacies. the client does not guarantee any minimum purchase quantities.